Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Dexcom : to Present at 38th Annual J.P. Morgan Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
01/06/2020 | 08:46am EDT

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare Conference on January 13, 2020.

The presentation, which will occur live at the Westin St. Francis Hotel in San Francisco, is scheduled to begin at approximately 8:00 AM PST and will be concurrently webcast.

The link to the webcast will be available on the Dexcom IR website at investors.dexcom.com by navigating to “Events and Presentations.”

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DEXCOM, INC.
03/30QUALCOMM : Names Heather Ace as Executive Vice President of Human Resources; Exe..
AQ
03/10DEXCOM INC : Change in Directors or Principal Officers (form 8-K)
AQ
03/06How Lipper Award-winning fund managers are playing coronavirus scare
RE
02/24DEXCOM : to Present at Cowen 40th Annual Healthcare Conference
BU
02/20DEXCOM : G6 Continuous Glucose Monitoring (CGM) System Receives CE Mark for Use ..
BU
02/17DEXCOM : G6® CGM System Now Available In Canada
AQ
02/17DEXCOM : and Companion Medical Announce Collaboration to Integrate Dexcom CGM Da..
AQ
02/17DEXCOM : Announces FDA Clearance of New Dexcom G6 Pro CGM
AQ
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/13DEXCOM : 4Q Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2020 1 750 M
EBIT 2020 227 M
Net income 2020 166 M
Finance 2020 4,07 M
Yield 2020 -
P/E ratio 2020 160x
P/E ratio 2021 99,7x
EV / Sales2020 14,1x
EV / Sales2021 11,3x
Capitalization 24 664 M
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 284,32  $
Last Close Price 269,27  $
Spread / Highest target 22,6%
Spread / Average Target 5,59%
Spread / Lowest Target -31,3%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategies
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.23.10%24 664
MEDTRONIC PLC-20.51%120 856
BAXTER INTERNATIONAL INC.-2.91%41 180
HOYA CORPORATION-5.74%32 156
TERUMO CORPORATION-3.23%25 993
ZIMMER BIOMET HOLDINGS-32.47%20 891